

/Kamiren XL
Kamiren CL - modified release tablets: 1 tab. contains Doxazosin mesilate 4.85 mg (corresponding to 4 mg of doxazosin), excipients: hypromellose; anhydrous Calcium phosphate; lactose monohydrate; Magnesium stearate; shell - dye Opadry white (hypromellose, titanium dioxide E171); macrogol 400;
in a package of 10, 30 or 90 pieces.
Kamiren HL has an antihypertensive effect.
Arterial hypertension of mild or moderate severity (monotherapy or in combination with other antihypertensive drugs), benign prostatic hyperplasia (symptomatic treatment).
Hypersensitivity to doxazosin and other quinazoline derivatives (prazosin, terazosin) or to other components of Kamiren HL;
age up to 18 years (efficacy and safety have not been established).
With caution:aortic or mitral stenosis;
impaired liver and / or kidney function;
orthostatic hypotension.
Pregnant women can be prescribed Kamiren CL only for health reasons, when the benefits to the mother outweigh the potential risk to the fetus / child. The safety of the drug in infants has not been established, therefore, nursing mothers are advised to stop breastfeeding during treatment with doxazosin.
In the treatment of hypertension:
In clinical trials, orthostatic hypotension, which in rare cases can lead to syncope, has been observed most often, especially at the beginning of treatment.
Body as a whole: asthenia, fatigue, malaise.
Cardiovascular: swelling, fainting.
Eliminating the alpha-adrenostimulating effects of epinephrine can lead to tachycardia and arterial hypotension.
Kamiren CHL is taken orally, 1 time per day, in the morning or in the evening, regardless of the time it comes in, without chewing and drinking plenty of water.
The usual dose of Kamiren CL is 4 mg (1 tab.) Per day.
In the dark place at a temperature of no higher than 25 ° C. Shelf life - 2 years.